Vapaliximab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameVapaliximab
Drug Alias NameHuvapBTT-1002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAmine oxidase, copper containing inhibitors
TargetsAmine oxidase, copper containing
Therapy Area/IndicationsRejection of organ transplantationInflammationAsthma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAcorda Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgSeikagakuAcorda Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationInflammationAsthma +[5] 

Other Information

ATC CodeN/A
Related LinksWikipedia